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Abstract
Background: Several mechanisms are present in the tumor microenvironment (TME) to impair cytotoxic T cell
responses potentially able to control tumor growth. Among these, the accumulation of adenosine (Ado)
contributes to tumor progression and represents a promising immunotherapeutic target. Ado has been shown to
impair T cell effector function, but the role and mechanisms employed by Ado/Ado receptors (AdoRs) in
modulating human peripheral and tumor-infiltrating lymphocyte (TIL) function are still puzzling.
Methods: CD8+ T cell cytokine production following stimulation was quantified by intracellular staining and flow
cytometry. The cytotoxic capacity of tumor infiltrating lymphocytes (TILs) was quantified by the chromium release
assay following co-culture with autologous or anti-CD3-loaded tumor cell lines. The CD8+ T cell metabolic fitness
was evaluated by the seahorse assay and by the quantification of 2-NBDG uptake and CD71/CD98 upregulation
upon stimulation. The expression of AdoRs was assessed by RNA flow cytometry, a recently developed technology
that we validated by semiquantitative RT-PCR (qRT-PCR), while the impact on T cell function was evaluated by the
use of selective antagonists and agonists. The influence of Ado/AdoR on the PKA and mTOR pathways was
evaluated by phosphoflow staining of p-CREB and p-S6, respectively, and validated by western blot.
Results: Here, we demonstrate that Ado signaling through the A2A receptor (A2AR) in human peripheral CD8+ T
cells and TILs is responsible for the higher sensitivity to Ado-mediated suppression of T central memory cells. We
confirmed that Ado is able to impair peripheral and tumor-expanded T cell effector functions, and we show for the
first time its impact on metabolic fitness. The Ado-mediated immunosuppressive effects are mediated by increased
PKA activation that results in impairment of the mTORC1 pathway.
Conclusions: Our findings unveil A2AR/PKA/mTORC1 as the main Ado signaling pathway impairing the immune
competence of peripheral T cells and TILs. Thus, p-CREB and p-S6 may represent useful pharmacodynamic and
efficacy biomarkers of immunotherapies targeting Ado. The effect of Ado on T cell metabolic fitness reinforces the
importance of the adenosinergic pathway as a target for next-generation immunotherapy.
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Background
Recently, it was discovered that activated T cells undergo
a pronounced mTOR-mediated metabolic switch [1–3],
and failure to reprogram metabolic activities leads to a hy-
poresponsive state, including exhaustion and anergy [4, 5].
In the tumor microenvironment (TME), multiple mecha-
nisms such as overexpression of immune checkpoint mol-
ecules [6] and loss of nutrients [7, 8] were recently shown
to impair T cell metabolic fitness, thus impairing immune
control of tumor growth [9, 10]. However, it remains
largely unexplored whether and how immunosuppressive
molecules, such as adenosine (Ado), impair T cell func-
tions by subverting their metabolic activity.
Extracellular Ado is produced by the sequential de-
phosphorylation of ATP catalyzed by two cell surface
ectonucleotidases, CD39 and CD73. In the TME, the
ATP released by cell death, the increased expression
of CD39 and CD73 and the decreased expression of
the adenosine deaminase (ADA)/CD26 complex lead
to the accumulation of Ado [11, 12]. The persistent
high concentration of Ado may become detrimental,
generating an immunosuppressive microenvironment
[13–18]. Mechanistically, Ado mediates multiple ef-
fects by binding the G-protein-coupled receptors A1,
A2A, A2B and A3 [19]. Signaling of A2A and A2B
adenosine receptors (A2AR, A2BR) through Gs pro-
teins increases cyclic AMP levels and protein kinase
A (PKA) activity [19–21]. Studies with selective ago-
nists/antagonists have revealed the key role of A2AR
in the suppression of T cell functions [15–17, 20].
However, the relative sensitivity of T cell subsets to
Ado and the relevant mediators downstream of Ado
receptors (AdoRs) have not yet been determined.
Here, we demonstrate that Ado immunosuppressive
effects on human CD8+ T cells are primarily exerted on
T central memory cells (TCM), likely due to their higher
levels of A2AR expression. Selective blockade of A2AR,
but not A2BR, restored CD8+ T cell functionality. Trig-
gering A2AR increased PKA activation (i.e., CREB
phosphorylation), resulting in impaired TCR signaling,
the mTORC1 (but not mTORC2) pathway (i.e., S6
phosphorylation), cytokine production and metabolic
fitness, both in the context of T cell polyclonal stimula-
tion and of tumor cell recognition and killing by au-
tologous tumor infiltrating lymphocytes (TILs).
Our findings unveil the A2AR/PKA/mTORC1 path-
way as the main axis for the Ado-mediated impair-
ment of T cell function and metabolic fitness. In line
with other studies evaluating the Ado pathway as a
relevant target for immunotherapy [13, 14, 16, 21],
we corroborate that blockade of A2AR has great po-
tential for next-generation immunotherapy, and we
propose p-CREB and p-S6 as potential biomarkers of
efficacy for validation in future clinical studies.
Methods
Subjects and specimen preparation
Human blood samples from healthy donors were col-
lected at the local Blood Transfusion Center Lausanne,
Switzerland, under IRB approval (Ethics Committee,
University Hospital of Lausanne-CHUV). Written in-
formed consent was obtained from all healthy subjects
and patients, in accordance with the Declaration of
Helsinki. Fresh anticoagulated blood diluted at a 1:2 ra-
tio in PBS was layered on lymphoprep (ratio of diluted
blood:lymphoprep 1.5:1). Mononuclear cells were iso-
lated by density gradient centrifugation (1800 rpm, 20
min centrifugation without break, room temperature),
washed twice and immediately cryopreserved in 90%
fetal calf serum (FCS) and 10% DMSO.
Informed consent from the cancer patients was ob-
tained based on the procedures approved by the same
IRB as mentioned above. Clinical characteristics are de-
scribed in Additional file 2: Table S2.
Freshly resected tumors not needed for histopatho-
logic diagnosis were transferred in transport media
(RPMI + 2% penicillin-streptomycin) in sterile con-
tainers at 4 °C. Tumors were then cut into 1–2 mm2
pieces and used freshly or cryopreserved in 90% hu-
man serum+ 10% DMSO.
Antibodies and reagents
Anti-CCR7 (CD197) Alexa Fluor 488 (clone G043H7),
anti-CCR7 (CD197) PE/Cy7 (clone G043H7), anti-
CD107a (LAMP-1) Brilliant Violet 510 (clone H4A3),
anti-CD16 Alexa Fluor 700 (clone 3G8), anti-CD19 Bril-
liant Violet 650 (clone HIB19), anti-CD3 Brilliant Violet
605 (clone UCHT1), anti-CD3 APC/Fire750 (clone SK7),
anti-CD4 Brilliant Violet 421(clone RPA-T4), anti-CD4
PE/Dazzle 594 (clone RPA-T4), anti-CD45RA Alexa Fluor
700 (clone Hl100), anti-CD56 PE (clone NCAM), anti-
CD71 PE/Cy7 (clone CY1G4), anti-CD73 PE/Dazzle 594
(clone AD2), anti-CD8 PE/Cy7 (clone RPA-T8), anti-CD8
Brilliant Violet 650 (clone RPA-T8), CD8 FITC (clone
SK1); anti-IL2 PE (clone MQ1-17H12), anti-PD1 (CD279)
Brilliant Violet 421 (clone EH12.2H7), and anti-TNF-α
PE/Cy7 (clone Mab11) were purchased from BioLegend.
Anti-CD39 Brilliant Violet 711 (clone TU66), anti-CD4
BUV496 (clone SK3), anti-CD45RA Brilliant Violet 510
(clone Hl100), anti-CD8 Pacific Blue (clone RPA-T8),
anti-CD98 PE (clone UM7F8), and anti-IFN-γ APC (clone
B27) were purchased from Becton Dickinson. The Anti-
phospho-CREBSer133 Alexa Fluor 647 (clone 87G3), un-
conjugated anti-phospho-S6Ser235/236, and unconjugated
anti-phospho-AktSer473 (clone 193H12) were purchased
from Cell Signaling Technology. The secondary antibody
goat anti-rabbit IgG H&L Alexa Fluor 488 was purchased
from Abcam. Stable adenosine (Ado), A2AR agonist CGS
21680, A2AR inhibitor ZM 241385, A2BR inhibitor PSB
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1115, PKA inhibitor KT 5720, rapamycin and AKT1/2 in-
hibitor MK 2206 were purchased from Sigma-Aldrich.
Anti-CD3 used for the redirected cytotoxicity assay was
generated by a hybridoma in house.
Virus-specific peptides
A peptide pool of CMV-EBV-Flu-specific peptides optimal
for CD8+ T cells has been purchased from JPT Peptide
Technologies. The following HLA-A2-restricted single pep-
tides have been synthetized by the peptide facility at the
Ludwig Cancer Institute of Lausanne: CMV-
NLVPMVATV, EBV-GLCTLVAML, and Flu-GILGFVFTL.
Cell cultures
Cell lines
The EBV-transformed B-cell line (generated in house), hu-
man leukemic lines: THP1, (catalog number (cn): TIB-202,
ATCC) and HL60 (cn: CCL-240, ATCC), prostate cancer
lines: DU145 (cn: HTB-81, ATCC) and PC3 (cn: CRL-
1435, ATCC), LNCaP (cn: CRL-1740, ATCC), breast
cancer cell line MCF-7 (cn: HTB-22, ATCC) and the mas-
tocytoma cell line P815 (cn: TIB-64, ATCC) were main-
tained in tissue culture flasks in RPMI supplemented with
10% FCS, amino acids and HEPES. All cell lines were peri-
odically tested for mycoplasma contamination and con-
firmed negative by PCR with mycoplasma-specific primers
(5′-ACTCCTACGGGAGGCAGCAGTA-3′ and 5′-
TGCACCATCTGTCACTCTGTTAACCTC-3′).
Human peripheral blood mononuclear cells (PBMCs)
PBMCs were cultured in RPMI supplemented with 5%
penicillin-streptomycin, 25 mM HEPES, and 8% heat-
inactivated FBS. When mentioned, assays were per-
formed in glucose-free RPMI supplemented with 5%
penicillin-streptomycin.
Tumor-infiltrating lymphocytes (TILs)
For TILs expansion, tumor tissues were dissected into
fragments of approximately 2 mm3. Each fragment was
plated individually in a single well of a 24-well plate and
stimulated with 6000 IU/ml rhIL-2 for 3 weeks. A rapid
expansion protocol (REP) was performed by stimulating
TILs with PHA 1 μg/ml, 3000 IU/ml rhIL2 (Proleukin,
Roche) and feeders. TIL culture media was RPMI sup-
plemented with 5% penicillin-streptomycin (Gibco), 25
mM HEPES, 1% L-glutamine (Gibco), 1% nonessential
amino acids (Gibco), 1% Na pyruvate (Gibco), 0.1% 2β-
mercaptoethanol (Gibco), and 8% heat-inactivated,
pooled human serum.
Melanoma cell lines
Autologous tumor cell lines were established from three
melanoma samples. Tissue was mechanically dissociated,
with a clamp and scalpel, and enzymatically dissected
using collagenase type I (Sigma-Aldrich) and deoxiribo-
nuclease I (Roche) for 45–60min at 37 °C. Tumor cell
suspensions were cultured in RPMI, 10% fetal bovine
serum (Gibco), and 1% penicillin-streptomycin (Gibco),
dispensed into 10-cm petri dishes, and transferred to T-
25 and T-75 flasks as cells expanded.
TIL/autologous tumor cell line cocultures
When described, cells were preincubated with the A2AR
antagonist ZM 241385 (30 μM) or the A2BR antagonist
PSB 1115 (100 μM) for 1 h and 30 min and then with
nothing or Ado (30 μM) for 2 h. After preincubation,
200,000 TILs/well were dispensed into a 96-well plate
containing, or not, the same number of autologous mel-
anoma tumor cells. Intracellular staining for cytokine
production, the cytotoxic assay or p-CREB and p-S6 flow
cytometry staining were then performed.
Cytokine production assay and intracellular staining
Cryopreserved blood mononuclear cells were stimulated
with anti-CD3/CD28 beads (bead-to-cell ratio = 1:2; Mil-
tenyi) or CMV−/EBV−/Flu-specific peptides (1 μM).
TILs were stimulated by anti-CD3/CD28 beads (bead-
to-cell ratio = 1:2; Miltenyi) or autologous tumor cell
lines. Stimulation was performed overnight at 37 °C in
the presence of GolgiPlug (1 μg/ml; BD) and anti-
CD107. When described, cells were preincubated with
the A2AR antagonist ZM 241385 (30 μM), the A2BR an-
tagonist PSB 1115 (100 μM), or the PKA inhibitor KT
5720 (30 μM) for 1 h 30 min and then with nothing, Ado
(30 μM), or the A2AR agonist CGS 21680 (30 μM) for
an additional 2 h. The time of incubation for Ado was
chosen as the time giving the lowest reduction in IFN-γ
production with no impact on cell survival. The time of
incubation of antagonists was chosen as the time needed
by ZM 241385 to fully prevent Ado inhibition of IFN-γ
production. Then, the cells were washed with PBS-2 mM
EDTA and stained extracellularly. First, cells were
stained for the surface markers CCR7 and CD45RA and
with a viability dye (Zombie UV, Biolegend) for 20 min
at 4 °C. Cells were then washed and permeabilized with
Cytofix/Cytoperm solution (30 min 4 °C, Fix and Perm
buffer, Becton Dickinson), washed with wash buffer
(Becton Dickinson) and stained with antibodies directed
to CD3, CD4, CD8, IFN-γ, TNF-α and IL-2 (20 min,
4 °C). After washing, the cells were resuspended in PBS
and analyzed by flow cytometry.
Functional avidity assessment
The functional avidity of virus-specific CD8+ T cell re-
sponses was assessed by performing limiting peptide di-
lutions (ranging from 1 μM to 10 pM) and measuring
cytokine production by flow cytometry. The peptide
concentration required to achieve a half-maximal IFN-γ
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response (EC50) was determined as described [22]. Pep-
tide stimulation and antibody staining were performed
as described in the cytokine production assay.
Functional sensitivity to ado assessment
Functional sensitivity to Ado of peripheral or expanded
tumor-infiltrating or peripheral CD8+ T cells was
assessed by stimulating cells overnight with anti-CD3/
anti-CD28-coated beads in the presence of decreasing
doses of Ado (ranging from 0 μM to 100 μM) and meas-
uring cytokine production by flow cytometry. The Ado
concentration required to achieve a half-maximal cyto-
kine response (IC50) was determined. Stimulation and
antibody staining were performed as described in the
cytokine production assay.
P-CREBSer133, p-S6Ser235/236 and p-AktSer473 flow cytometry
staining
Peripheral or expanded tumor-infiltrating CD8+ T cells
were preincubated with the A2AR antagonist ZM 241385
(30 μM), the A2BR antagonist PSB 1115 (100 μM), or the
PKA inhibitor KT 5720 (10 μM) for 1 h and 30min and
then with nothing, Ado (30 μM), or the A2AR agonist CGS
21680 for 2 h (30 μM). Rapamycin (RAPA, 20 μM) was
used as a positive control for mTORC1 (p-S6Ser235/236) in-
hibition, and MK2206 (100 nM) was used as a positive con-
trol for mTORC2 (p-AktSer473) inhibition. To evaluate p-
S6Ser235/236 or p-AktSer473, CD8+ T cells were stimulated for
3 h with anti-CD3/anti-CD28-coated beads or autologous
tumor cell lines. Then, the cells were washed with PBS-2
mM EDTA and stained extracellularly. First, cells were
stained for the surface markers CCR7, CD45RA and/or
CD98, CD71 and with a viability dye (Zombie, Biolegend)
for 20min at 4 °C. Cells were then washed and fixed/
permeabilized with the Transcription Factor Staining Buffer
Set (eBioscience). Cells were stained with antibodies di-
rected to p-CREBSer133, p-S6Ser235/236 and p-AktSer473 (20
min, 4 °C). p-S6Ser235/236 and p-AktSer473 were not conju-
gated to a fluorochrome; therefore, after washing, a pread-
sorbed secondary goat anti-rabbit IgG H&L antibody Alexa
Fluor® 488 (Abcam) was added. After washing, the cells
were resuspended in PBS and analyzed by flow cytometry.
Measure of metabolic parameters by flow cytometry
The following assays were performed in glucose-free
medium. 2-[N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)a-
mino]-2-deoxy-d-glucose (2-NBDG, Invitrogen) uptake,
CD98 and CD71 upregulation were carried out with
magnetically isolated CD3+ T cells (Pan T Cell Isolation
Kit, Miltenyi), which were preincubated with ZM
241385 (30 μM), PSB 1115 (100 μM), and KT 5720
(Sigma) for 1 h and 30 min and then with nothing, Ado
(30 μM), CGS 21680 or BAY 60–6583 (Sigma) for 2 h
and finally activated overnight by anti-CD3/CD28 beads.
T cells were then stained with antibodies directed to
CD3, CD4, CD8, CCR7, and CD45RA and when needed
CD98 and CD71 (20 min 4 °C). To evaluate glucose
uptake, cells were washed and incubated with 100 μM 2-
NBDG at 37 °C for 20 min prior to fluorescence meas-
urement by flow cytometry.
Detection of AdoR mRNA by RNA flow cytometry (Prime
Flow RNA, Affymetrix)
Human PBMCs were thawed, and when needed, total
CD3+ cells were isolated by negative selection with a
Pan T Cell Isolation Kit (MACS technology, Miltenyi).
Cells were transferred to RNA Flow staining tubes
(RNAse free; provided with the kit). Mouse splenocytes
were also taken as a negative control and stained for
anti-mCD45. Cells were first stained at the surface for
CD3, CD4, CD8, CD56, CD16, CD19, CD14, CCR7, and
CD45RA (20 min 4 °C) and then stained for AdoR
mRNA following the manufacturers’ instructions [23].
Briefly, tubes were centrifuged at 2500 rpm for 5 min.
Cells were then fixed and permeabilized in the presence
of RNAse inhibitors. A second step of fixation was per-
formed for 1 h at room temperature. Mouse cells were
added to each human sample as an internal negative
control or in a separate tube. Cells were then washed
twice in wash buffer, and target probes for AdoRs were
added and incubated for 2 h at 40 °C. After centrifuga-
tion, the cells were left overnight at 4 °C. PreAmp-mix
and Amp-mix were then added successively with an in-
cubation time of 1 h and 30min at 40 °C each and two
washes between each incubation step. Finally, labeled
custom probes directed against ADORA2A, ADORA2B,
ADORA1 and ADORA3 were added, and the cells were
washed before flow cytometry analysis.
Flow cytometry analysis
Flow cytometry acquisition was performed with an
LSRFortessa flow cytometer (BD Biosciences). Flow cy-
tometry analysis was performed with FlowJo software
(Version 10.2, Treestar). Data were analyzed by Prism v7.
Preparation of cellular extracts and western blot analysis
Whole-cell extracts were prepared using RIPA buffer
(50 mM Tris, 150mM NaCl, 1% Triton X-100, 1% so-
dium deoxycholate, 0.1% sodium dodecyl sulfate (SDS),
1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM
Na3VO4, 5 mM NaF, and 1% cocktail protease inhibi-
tors; Sigma). The protein concentration was measured
using the Pierce™ BCA Protein Assay Kit (Thermo Scien-
tific). Equal amounts of protein (40 μg/sample) were sep-
arated by electrophoresis in a 12% denatured
polyacrylamide gel and blotted onto nitrocellulose mem-
branes (Bio-Rad). The membranes were blocked for 1 h
in 5% low-fat milk in PBS with 0.1% Tween 20 (PBST)
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at room temperature. Then, the filters were incubated
with the following primary antibodies overnight at 4 °C:
Phospho-CREB (Ser133) (9198, Cell Signaling, USA; di-
luted 1:1000); CREB (9197, Cell Signaling, USA; diluted 1:
1000); Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)
(9101, Cell Signaling, USA; diluted 1:1000); p44/42 MAPK
(Erk1/2) (9102, Cell Signaling, USA; diluted 1:1000);
Phospho-Akt (Ser473) (4058, Cell Signaling, USA; diluted
1:1000); Akt (pan) (2920, Cell Signaling, USA; diluted 1:
2000); Phospho-S6 Ribosomal Protein (Ser235/236) (2211,
Cell Signaling, USA; diluted 1:1000); S6 Ribosomal Protein
(2317, Cell Signaling, USA; diluted 1:1000); and α-Tubulin
(3873, Cell Signaling, USA; diluted 1:1000). The mem-
branes were washed 3 times with PBST and then incu-
bated with (HRP)-conjugated anti-rabbit or anti-mouse
antibodies for 2 h at room temperature. The membranes
were then washed 3 times (10min in PBST), and proteins
were visualized by the ECL chemiluminescence method.
The immunoreactive bands of proteins were acquired by
using the GBOX Chemi XX6 system (Syngene).
Cytotoxic assay
When described, TILs were preincubated with the
A2AR antagonist ZM 241385 (30 μM) for 1 h and 30
min and then with nothing or Ado for 2 h (30 μM). TILs
were then dispensed into a 96-well plate, in triplicate, at
decreasing densities: from 100,000 to 1000 cells/well.
Autologous melanoma cell lines or P815 cell lines
(unloaded or loaded with anti-CD3) were labelled with
51chromium for 45min at 37 °C, and after 3 washing steps,
1000 cells were dispensed into each TIL-containing well.
In addition, for calculation of specific lysis, 1000 cells were
also dispensed into four wells containing only tumor
medium (spontaneous release) and into four wells con-
taining 1M HCL (maximum release).
Effector and target cells were incubated in a total vol-
ume of 200 μl of RPMI 10% FBS or HCL for 4 h at 37 °C,
5% CO2. The plates were centrifuged for 3 min at 230×g.
Forty microliters of the culture supernatants was trans-
ferred to a LumaPlate-96 (PerkinElmer, Turku, Finland)
and, after drying the plates, read on a TopCount NXT
(Packard, Meriden, USA). The percentage lysis was cal-
culated by the following formula:
%of Lysis ¼ ðexperimental release spontaneous release½ Þ
= maximum release spontaneous releaseð Þ
 100:
Semiquantitative RT-PCR (qRT-PCR) (SYBR GREEN)
To measure AdoR expression, CD8+ T cells were iso-
lated from cryopreserved blood mononuclear cells by
magnetic activated cell sorting (MACS technique) using
a CD8+ T Cell Isolation Kit (Miltenyi Biotech) according
to the manufacturer’s instructions. The MCF-7, EBV-B,
PC3, THP-1 and HL-60 cell lines were also used as in-
ternal controls for validation. AdoR and HIF-1α expres-
sion were measured in total TILs. Total cellular RNA was
isolated by the RNeasy Micro kit (Qiagen). cDNA was
synthesized from 250 ng of total RNA using the Super-
script II system according to the manufacturer’s protocol
(Life Technologies). PCR reactions contained cDNA, 2x
qPCR Master Mix (KAPA Biosystems), and 2 μM of for-
ward and reverse primers. qRT-PCR was performed on an
Applied Biosystems® 7500 Fast Real-Time PCR instru-
ment. Each reaction was performed in three replicates,
with beta-2-microglobulin (β2M) as an internal control
gene for normalization. Raw Ct values were imported into
Excel, and the expression levels of the PCR products rela-
tive to β2M were calculated using the 2 −ΔCt method.
The primer sequences used were as follows: β2M sense,
5′-CCAGCAGAGAATGGAAAGTC-3′; antisense, 5′-
GATGCTGCTTACATGTCTCG-3; ADORA1 sense, 5′-
CCTCCATCTCAGCTTTCCAG-3′ (DOI: 10.1182/blood-
2013-02-482406); antisense, 5′-AGTAGGTCTGTGGC
CCAATG-3′, ADORA2A sense, 5′- CTCCGGTACA
ATGGCTTGGT-3′; antisense, 5′- TGGTTCTTGCCCTC
CTTTGG-3′, ADORA2B sense, 5′-ATGCCAACAG
CTTGAATGGAT-3′; antisense, 5′-GAGGTCACCT
TCCTG GCAAC-3′, ADORA3 sense, 5′-TTGACC
AAAAGGAGGAGAAGT-3′; antisense, 5′- AGTCAC
ATCTGTTCAGTAGGA G-3′. HIF-1α sense, 5′-GGC
AGC AAC GAC ACA GAA ACT GA-3′; antisense, 5′-
TGA TCC TGA ATC TGG GGC ATG GT-3′ (DOI:
https://doi.org/10.1038/s41598-017-00508-x).
The efficiency of each primer set was tested by generat-
ing a standard curve using relative positive control sam-
ples for each primer (MCF-7, EBV-B, PC3 and HL-60 for
adenosine receptor A1, A2A, A2B and A3, respectively).
All primers were tested by qRT-PCR using a two-fold ser-
ial dilution of cDNA and water as a nontemplate control
to determine the amplification efficiency and specificity.
The amplification efficiency for each primer was deter-
mined from the linear slope of the standard curve; only
primers with a standard curve slope between − 3.1 and −
3.4 were used for further quantification.
Analysis of the relative changes (arbitrary units) in
gene expression required calculations based on the
threshold cycle (Ct: the fractional cycle number at which
the amount of amplified target reaches a fixed thresh-
old). The threshold cycles of the cell subsets were then
normalized based on the threshold cycle of the house-
keeping gene (β2M) to obtain the ΔCt.
Measure of glycolytic and phospho-oxidative metabolism
(seahorse assay)
Magnetically isolated CD3+ T cells were left uncondi-
tioned or incubated with ZM 241385 (30 μM) and/or
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Ado (30 μM). Cells were then stimulated overnight with
anti-CD3/CD28 beads, and the seahorse assay was per-
formed. For the extracellular flux assay, the sensor cart-
ridge was hydrated overnight in Seahorse XF Calibrant
at 37 °C in a non-CO2 incubator. A total of 4 × 10
5 hu-
man T cells with different treatment conditions were
seeded in a Seahorse Bioscience culture plate for 30 min.
OCR and ECAR were then measured by an XF96 Sea-
horse Extracellular Flux Analyzer following the manufac-
turer’s instructions. During the seahorse assay, cells were
treated with oligomycin (0.5 μM), FCCP (2 μM), rote-
none (0.5 μM), antimycin A (0.5 μM) and 2-DG (50
mM). Each condition was performed in 3–6 replicates.
Statistical analysis
Statistical analysis was performed with Prism software
(Version 7, GraphPad) using nonparametric and para-
metric paired (Friedman or Wilcoxon or t test) and un-
paired (Kruskal-Wallis or Mann-Whitney) tests as
indicated. For multiple comparisons, adjusted P-values
were calculated by one-way ANOVA followed by Dunn’s
test. Correlations were assessed by the nonparametric
Spearman’s test.
Results
Human CD8+ T cell memory subsets are differentially
affected by ado
Activated naïve CD8+ T cells differentiate in memory sub-
sets with distinct phenotypic and functional properties
[24]. The differentiation and maintenance of murine naïve
CD8+ T cells is negatively impacted by A2AR signaling
[25]. However, the differences in the sensitivity to Ado of
memory subsets in human CD8+ T cells have not yet been
explored. We identified the major CD8+ T cell memory
subsets according to their differential expression of CCR7
and CD45RA (i.e., T central memory-TCM, T effector
memory-TEM, T terminally differentiated-TEMRA; Add-
itional file 1: Figure S1a, Additional file 2: Table S1), and
we assessed the relative sensitivity to Ado by measuring
cytokine production following polyclonal or antigen-
specific stimulation (Fig. 1a-b, Additional file 2: Table S1).
Exposure to Ado decreased cytokine production (i.e., IFN-
γ, TNF-α, and IL-2) and partially decreased the degranula-
tion activity (i.e., CD107a mobilization) in CD8+ T cells
(Fig. 1a-b and Additional file 1: Figure S1 b-d), consistent
with previous studies [14, 16, 17, 20]. Ado mediated sup-
pression of responses to both polyclonal stimulation (i.e.,
anti-CD3/anti-CD28-coated beads) (Fig. 1a-b and
Additional file 1: Figure S1b-d) and viral epitopes
(Fig. 1b and Additional file 1: Figure S1c) but not
stimulation with ionomycin or phorbol-12-myristate-
13-acetate (PMA) (Additional file 1: Figure S1b,e). Of
interest, among the distinct T cell subsets, TCM were more
sensitive to Ado, with deeper suppression of cytokine
production than those of the TEM and TEMRA subsets (Fig.
1b and Additional file 1: Figure S1f).
The functional avidity of CD8+ T cells, also called anti-
gen sensitivity, is measured as the peptide concentration
able to mobilize 50% of the maximal response (EC50).
The functional avidity of T cells is independent of the
magnitude of a response measured at saturating antigen
concentrations [26] and is usually associated with super-
ior control of virus replication or tumor growth [22, 27].
We evaluated the functional avidity of a panel of virus-
specific polyclonal CD8+ T cells exposed to decreasing
peptide concentrations. We observed that Ado signifi-
cantly reduced the functional avidity of all virus-specific
CD8+ T cells (Fig. 1c-d), with the strongest effect ob-
served in the TCM subset (Fig. 1c-d). These data indicate
that Ado limits the ability of T cells to respond to tar-
gets expressing cognate antigens.
A2AR expression levels dictate ado sensitivity in human
CD8+ T cells
Our data suggest that TCM cells are the most sensitive
subset to functional blunting by Ado. To substantiate this
further, we quantified the functional sensitivity to Ado of
each memory subset by determining the Ado concentra-
tion inhibiting 50% of the maximal response (IC50 of the
cytokine production). We confirmed that CD8+ TCM cells
displayed higher sensitivity to Ado than TEM and TEMRA
cells (Fig. 2a-b and Additional file 1: Figure S2a).
We therefore hypothesized that the differential sensi-
tivity to Ado may be explained by TCM cells expressing
higher AdoR levels than the other memory subsets. Due
to the lack of antibodies for flow cytometry analyses for
A1R and A3R, we established RNA staining for flow cy-
tometry (PrimeFlow RNA assay) [23] (Additional file 1:
Figure S2b) to determine the expression of all four
ADORs (i.e., ADORA1, ADORA2A, ADORA2B and
ADORA3) in primary human CD8+ T cells. Moreover,
we used semiquantitative real-time PCR (qRT-PCR) as a
validation tool. To include positive controls for each re-
ceptor tested, we evaluated AdoR expression in distinct
cell lines: EBV-transformed B cell line, human leukemic
lines (THP-1 and HL-60), prostate cancer lines (DU-145
and PC-3, LNCaP) and a breast cancer cell line (MCF-7)
(Additional file 1: Figure S2c). AdoR expression data ob-
tained from qRT-PCR analysis correlated with flow cy-
tometry values in both cell lines and primary CD8+ T
cells (Additional file 1: Figure S2d-e). A correlation was
also found in CD8+ T cells when only A2AR expression
was considered (Additional file 1: Figure S2e). Overall,
these data indicate that the PrimeFlow RNA assay is a
suitable technology for the relative quantification of
AdoR expression in human CD8+ T cells. We also mea-
sured A2AR and A2BR expression with antibodies by
flow cytometry in CD8+ T cells and found a correlation
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with A2AR expression measured by PrimeFlow RNA
(Additional file 1: Figure S2f-g). Moreover, we confirmed
the lower/undetectable expression of A2BR by CD8+ T
cells (Additional file 1: Figure S2f, h).
We then evaluated AdoR expression in total CD8+ T
cells and in different memory subsets ex vivo. Of inter-
est, A2AR was expressed at a higher percentage than
other AdoRs in total CD8+ T cells (Fig. 2c). Among the
memory subsets, it was predominantly expressed by
CD8+ TCM cells, similar to naïve CD8
+ T cells (Fig. 2d).
These data strongly suggest that the high sensitivity of
CD8+ TCM cells to Ado is associated with their high ex-
pression of A2AR. In addition, our results not only sup-
port the role of A2AR as a critical player in Ado-
mediated suppressive effects in CD8+ T cells but also in-
dicate that A2AR expression quantitatively dictates
sensitivity to Ado. This was further corroborated by the
positive correlation between A2AR expression in CD8+
T cells and the Ado-mediated fold change (i.e., decrease)
in IFN-γ production (Fig. 2e), which was not observed
for A2BR (Additional file 1: Figure S3a).
Furthermore, we evaluated whether blocking A2AR or
A2BR with selective inhibitors (ZM 241385 and PSB 1115,
respectively) would prevent the Ado-mediated reduction of
cytokine production. The blockade of A2AR, but not
A2BR, was able to circumvent the immunosuppressive ef-
fects of Ado on CD8+ T cells (Fig. 2f). The selective A2AR
agonist CGS 21680 was also able to reduce IFN-γ produc-
tion in CD8+ T cells (Fig. 2f). Consistent with what was
already shown in the presence of Ado (Fig. 1b), CGS 21680
primarily affected the TCM subset (Additional file 1: Figure
S3b). The preventive action of A2AR- or A2BR-selective
Fig. 1 Ado-mediated immunosuppression of T cell function depends on the differentiation stage. a Representative example and b cumulative
data showing the Ado-mediated fold change in IFN-γ production in total and in distinct memory CD8+ T cell subsets (TCM, TEM, and TEMRA)
stimulated overnight with anti-CD3/anti-CD28-coated beads (n = 12) or CMV−/EBV−/Flu-specific peptides (n = 11). The 25th to 75th percentiles,
the median and min-max of the values are presented. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Wilcoxon and one-way ANOVA tests. c
Representative example and d cumulative data of the virus-specific CD8+ T cell functional avidity measured in the presence or absence of Ado in
total (n = 12) and in distinct memory CD8+ T cell subsets (TCM, TEM, and TEMRA) (n = 6). Wilcoxon test
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inhibitors was equal in all the differentiation subsets evalu-
ated (data not shown). The blockade of A2AR or A2BR
alone did not affect cytokine production significantly (Add-
itional file 1: Figure S3c). Finally, selective A2AR blockade
also efficiently prevented Ado-mediated immunosuppres-
sion of virus-specific CD8+ T cells (Fig. 2g).
Taken together, these data not only confirm A2A as
the main receptor responsible for Ado-mediated im-
munosuppression but also highlight the relevance of
A2AR expression levels in quantitatively determining
Ado suppressive effects in primary human CD8+ T cells.
Ado/A2AR triggers PKA, impairing TCR/mTORC1 signaling
and metabolic/effector functions in CD8+ T cells
Ado-mediated activation of A2AR increases intracellular
cAMP levels [28], and many of the downstream effects
of cAMP elevation are dependent upon PKA activation
[19, 29]. Of interest, the selective inhibition of the PKA
pathway in CD8+ T cell clones can prevent Ado-induced
suppression of cytokine production [20]. We therefore
investigated whether molecular mediators of PKA signal-
ing were activated by Ado in primary human CD8+ T
cells. Basal p-CREB levels increased in the presence of
Ado or CGS 21680, which is a selective A2AR agonist
(Fig. 3a and Additional file 1: Figure S4a-b). This effect
was prevented by both the PKA-specific inhibitor KT
5720 (Fig. 3a and Additional file 1: Figure S4a-b) and the
selective A2AR antagonist ZM 241385 (Fig. 3a and Add-
itional file 1: Figure S4a-b), while it was not affected by
the selective A2BR antagonist (PSB 1115, Fig. 3a). All
memory T cell subsets were influenced by Ado (Add-
itional file 1: Figure S4c), while CGS 21680 mostly af-
fected the TCM subset (Additional file 1: Figure S4c),
mirroring the functional data (Fig. 1).
Consistent with the increase in PKA activation and
previous observations [21, 30], we observed that Ado re-
duces TCR-dependent ERK phosphorylation in primary
human CD8+ T cells, reflecting impaired TCR signaling.
Notably, this effect was dependent upon A2AR/PKA sig-
naling (Additional file 1: Figure S4d-e).
Fig. 2 A2AR expression levels are correlated with the extent of Ado-mediated immunosuppression. a Representative example and b cumulative
data of the functional sensitivity (EC50 of IFN-γ production) to Ado measured in distinct CD8
+ T cell memory subsets after overnight stimulation
by anti-CD3/CD28 beads in the presence of decreasing concentrations of Ado (n = 12). c Cumulative data of AdoR expression (i.e., ADORA2A (n =
22), ADORA2B (n = 22), ADORA1 (n = 10), and ADORA3 (n = 10)) measured by RNA flow in total CD8+ T cells. d Cumulative data of A2AR measured
by RNA flow in distinct CD8+ T cell memory subsets (n = 16). e Correlation between A2AR expression measured by RNA flow and the Ado-
mediated fold change in IFN-γ production in total CD8+ T cells. Spearman’s test, n = 9. f Cumulative data of the fold change in IFN-γ production
by CD8+ T cells stimulated overnight with anti-CD3/CD28 beads in the presence of the indicated combinations of Ado, A2AR agonist (CGS 21680)
and A2AR/A2BR antagonists (ZM 241385 and PSB 1115, respectively). g Cumulative data showing the fold change in IFN-γ production by CD8+ T
cells stimulated overnight with virus-specific peptides in the presence of the indicated combinations of Ado and A2AR antagonist (ZM 241385)
(n = 6). In all box charts, the 25th to 75th percentiles, the median and min-max of the values are presented; *P < 0.05, **P < 0.01, ***P < 0.001.
Wilcoxon and/or one-way ANOVA tests
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Since the mTOR pathway is pivotal for complete T cell
activation and induces potent effector functions [4, 31, 32],
we evaluated whether Ado/A2AR signaling could affect
mTOR triggering in a PKA-dependent manner. To this
end, we assessed the phosphorylation of downstream effec-
tors of mTORC1 and mTORC2, i.e., S6 (p-S6; Additional
file 1: Figure S5a-b) and AktSer473 (p-AktSer473; Additional
file 1: Figure S5c-d) after polyclonal CD8+ T cell stimula-
tion. Ado signaling markedly impaired phosphorylation
of S6 (Fig. 3b and Additional file 1: Figure S5a-b) but
not of AktSer473 (Additional file 1: Figure S5c-e). These
data indicate that the mTORC1, but not the mTORC2,
complex is a target of Ado-mediated signaling in pri-
mary human CD8+ T cells. Importantly, this effect was
mediated by A2AR activation since the selective A2AR
agonist CGS 21680 also reduced S6 phosphorylation
(Fig. 3b), and the selective inhibitor of A2AR (ZM
241385), but not A2BR (PSB 1115), was able to prevent
both Ado and CGS 21680 effects (Fig. 3b). Interestingly,
S6 phosphorylation was reduced in both TCM and TEM
subsets but not in the TEMRA subset (Additional file 1:
Figure S5f). Additionally, the selective agonist of A2AR
(CGS 21680) predominantly affected the TCM compart-
ment (Additional file 1: Figure S5f), mirroring the func-
tional data (Fig. 1). Finally, blockade of the PKA
pathway prevented Ado-mediated inhibition of
mTORC1 activation (Fig. 3b), thus indicating that Ado
impaired mTORC1 signaling through PKA activation.
These data strongly suggest that Ado/A2AR signaling
impairs mTORC1 activation in human CD8+ T cells
through PKA, likely due to the PKA-dependent inhib-
ition of TCR signaling.
mTOR is the main complex responsible for both meta-
bolic rewiring [3, 33] and augmented effector functions
following TCR-mediated activation [34, 35]; thus, we
assessed whether Ado also impaired CD8+ T cell meta-
bolic fitness. Upon CD8+ T cell activation, Ado impaired
metabolic activity of both OXPHOS and glycolysis in an
A2AR-dependent manner (Fig. 3c). However, Ado in-
duces more severe impairment of ECAR, suggesting that
cells prefer to utilize oxygen consumption to sustain
metabolic needs in this condition.
This was further confirmed by the Ado-mediated im-
pairment of CD71/CD98 expression and of 2-NBDG
(glucose analog) uptake (Fig. 3d and Additional file 1:
Figure S6a). The selective inhibition of A2AR, but not of
A2BR, prevented the Ado-mediated effects (Fig. 3d).
Among the memory CD8+ T cell subsets, TCM cells were
the most affected (Additional file 1: Figure S6b). Notably,
both PKA and A2AR inhibition were able to prevent
Ado-mediated impairment of metabolic fitness and cyto-
kine production (Fig. 3d-e).
Taken together, these results strongly suggest that the
Ado/A2AR-mediated increase in PKA activation in
primary human CD8+ T cells leads to subsequent im-
pairment in metabolic fitness and effector functions,
likely due to the reduction in TCR signaling and
mTORC1 activation.
Ado suppresses TILs activation and tumor recognition
Ado is a mediator of TME immunosuppression and may
limit the success of immunotherapy, notably the adop-
tive cell transfer of tumor infiltrating lymphocytes (TILs)
[13, 36]. Since little is known regarding the susceptibility
of human TILs to Ado-mediated suppression and the
Ado receptors involved [16], we evaluated the capacity
of selective A2AR and A2BR inhibitors to prevent Ado
immunosuppression in human TILs. TILs were ex-
panded with the REP (rapid expansion protocol) from
tumoral or inflamed/normal prostate (n = 8), colon can-
cer metastasis (n = 4) and metastatic melanoma (n = 6)
(Additional file 2: Table S2); cell cultures with heteroge-
neous CD4+/CD8+ T cell ratios were obtained according
to the tumor evaluated (Additional file 1: Figure S7a).
Although heterogeneous (Additional file 1: Figure S7b),
the cytokine production capacity of CD8+ TILs was con-
sistently suppressed by Ado (Additional file 1: Figure
S7c). In line with the effects of Ado on peripheral T
cells, inhibitors of A2AR prevented the Ado-mediated
suppression of CD8+ TILs (Fig. 4a and Additional file 1:
Figure S7c). Surprisingly, in prostate-derived samples,
A2BR blockade was also able to prevent the Ado effect
(Fig. 4a and Additional file 1: Figure S7c). However, we
did not find any impact of A2AR or A2BR inhibitors on
the TIL expansion capacity (data not shown). We also
evaluated the sensitivity of CD8+ TILs to Ado and com-
pared it to circulating CD8+ T cells from healthy donors
and cancer patients in resting conditions (ex vivo) or
after in vitro expansion. Despite high variability, we ob-
served that CD8+ TILs and circulating CD8+ T cells had
an overall similar sensitivity (IC50) to Ado (Fig. 4b). To
gain further insight into the AdoR responsible for Ado-
mediated immunosuppression in TILs, we evaluated
AdoR expression by qRT-PCR in total TIL products. As
for the REP-expanded healthy peripheral T cells, TILs
predominantly expressed A2AR and lacked A1R and
A3R (Additional file 1: Figure S7d). However, TILs
showed higher expression of A2BR in some cases, in
particular the ones derived from prostate tissues (Add-
itional file 1: Figure S7d). Notably, we found a correl-
ation between A2BR expression and the capacity of the
A2BR antagonist to prevent the Ado-mediated reduction
in IFN-γ production (Fig. 4c). The higher expression of
A2BR can only be partially explained by the T cell acti-
vation status. Indeed, CD8+ T cells stimulated moder-
ately and transiently upregulated A2BR in vitro at day 3
(Additional file 1: Figure S7e).
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Previous data support the hypothesis that hypoxia
could induce the activation of the CD73-A2AR adeno-
sine pathway and that A2AR expression was positively
correlated in head and neck squamous cell carcinoma
tissues [18, 37, 38]. However, we did not find a correl-
ation between the expression of HIF-1α and A2AR in
the expanded TILs (Additional file 1: Figure S7f).
Ado can inhibit the ability of TILs to recognize and
kill target cells loaded with the melanoma differentiation
antigen MART125–36 peptide [39]. However, the effect of
Ado on autologous tumor cell recognition was not ad-
dressed. We first characterized AdoR expression in 6 au-
tologous melanoma cell lines (Additional file 2: Table
S2) by qRT-PCR and compared it to AdoR expression in
TILs expanded from the same lesion. In contrast to
TILs, tumor cells expressed A2AR at lower levels than
A2BR and at levels comparable to A1R and A3R (Add-
itional file 1: Figure S8a). We then evaluated whether
Ado could impair the ability of TILs to respond to au-
tologous tumor cells in vitro. Of interest, Ado was able
to reduce cytokine production, cytotoxic activity and
metabolic fitness of melanoma-derived TILs cocultured
with autologous tumor cells (Fig. 4d-g and Additional
file 1: Figure S8b-c). In the redirected killing assay, the
maximum frequency of cell lysis was 100% for all pa-
tients tested, and the suppressive effect of Ado on
Fig. 3 Ado/A2AR signaling modulates PKA and mTORC1 activation and impairs CD8+ T cell metabolic fitness and cytokine production. a
Cumulative data of p-CREB expression in CD8+ T cells treated with the indicated combinations of Ado, A2AR agonist (CGS 21680), A2AR/A2BR
antagonists (ZM 241385 and PSB 1115, respectively) and the PKA inhibitor KT570 (n = 7). b Cumulative data of p-S6 expression in CD8+ T cells
treated with the indicated combinations of Ado, A2AR agonist (CGS 21680), A2AR/A2BR antagonists (ZM 241385 and PSB 1115, respectively), the
PKA inhibitor KT570 or the mTOR inhibitor rapamycin (RAPA) and stimulated for 3 h by anti-CD3/anti-CD28-coated beads. c Representative
example of 3 independent experiments depicting the OXPHOS (measured as the oxygen consumption rate; OCR) and the glycolytic (measured as
the extracellular acidification rate; ECAR) metabolism in CD8+ T cells stimulated overnight by anti-CD3/CD28-coated beads in the presence of the
indicated combinations of Ado and the A2AR antagonist ZM 241385. d Cumulative data of CD71 and CD98 expression or 2-NBDG uptake in
CD8+ T cells treated with the indicated combinations of Ado and A2AR/A2BR antagonists (ZM 241385 and PSB 1115, respectively) or the PKA
inhibitor KT570 and stimulated overnight by anti-CD3/anti-CD28-coated beads (n = 6, n = 7 and n = 8 from left to right). e Cumulative data of the
fold reduction in CD8+ T cell IFN-γ production after treatment with combinations of Ado and A2AR antagonist (ZM 241385) or the PKA inhibitor
KT570 and stimulated overnight by anti-CD3/anti-CD28-coated beads (n = 5). In all box charts, the 25th to 75th percentiles, the median and min-
max of the values are presented; *P < 0.05, **P < 0.01, ***P < 0.001. Wilcoxon and/or one-way ANOVA tests
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cytotoxic function was almost undetectable (less than
20% reduction for any ratio considered) (Additional file
1: Figure S8d). In contrast, in the autologous setting,
Ado inhibition was more pronounced, reaching a 50%
reduction for some of the ratios tested where the max-
imum level of cell lysis was approximately 20% (Mel002,
Mel007, and Lau1015) (Fig. 4e). The lowest effect was
observed for patients Mel0011 and Lau50, where the
cytotoxicity was naturally very high (91 and 100%). We
could not test the effect of Ado in patient Lau1660 due
to a low overall killing capacity (less than 10%). In the
autologous setting, when the highest lysis values were
considered (effector:target ratio E:T = 100:1), a signifi-
cant reduction of cytotoxicity was observed in the pres-
ence of Ado, which was prevented by A2AR blockade
(ZM 241385) (Fig. 4f). These observations suggest that
in a physiological setting where tumor rejection antigens
may be poorly expressed by tumors or when TILs con-
tain limited frequencies of tumor antigen-specific T
cells, then Ado may play an important role in preventing
tumor cell killing by activating A2AR signaling. The
variability in the Ado effect observed at different E:T
Fig. 4 Ado impairs TIL effector functions and autologous tumor cell recognition. a Cumulative data of the fold change in CD8+ TIL IFN-γ
production in the presence of the indicated combinations of Ado, A2AR agonist (CGS 21680) and A2AR/A2BR antagonists (ZM 241385 and PSB
1115, respectively) (n = 14). The left graph shows all the TIL samples analyzed, while the right graph only shows prostate-derived samples. b
Cumulative data of the functional sensitivity (IC50 of IFN-γ production) to Ado measured in resting or expanded peripheral CD8+ T cells (n = 5)
derived from HD or patients and in CD8+ TILs (n = 10) derived from patient tissues. The functional sensitivity was measured after overnight
stimulation by anti-CD3/CD28-coated beads in the presence of decreasing concentrations of Ado. c Correlation between A2BR expression
measured by qRT-PCR and the Ado-mediated fold change in IFN-γ production in CD8+ TILs. Spearman’s test, n = 13 (n = 8 for the prostate
sample analysis). d Cumulative data of the fold change in IFN-γ and TNF-α production by TILs stimulated overnight by autologous tumor cells in
the presence of Ado or ZM 241385 + Ado. (n = 6) e Each graph represents cytotoxicity curves for one patient quantified in the absence of Ado, in
the presence of Ado or ZM 241385 + Ado. Data are presented as normalized to the cytotoxicity measured in the absence of Ado at the
effector:target (E:T) ratio of 100:1. Cytotoxicity was measured by coincubating TILs for 4 h with autologous tumor cells; measurements were
performed in triplicate. f Cumulative data of the fold change in cytotoxicity in the presence of Ado or ZM 241385 + Ado (n = 5). g Cumulative
data of the fold change in CD71 and CD98 expression by TILs stimulated overnight by autologous tumor cells in the presence of Ado or ZM
241385 + Ado (n = 6). h Cumulative data of the fold change in p-CREB and p-S6 expression by TILs stimulated for 3 h by autologous tumor cells
in the presence of Ado or ZM 241385 + Ado (n = 6). In all charts, each dot represents a patient, and the mean and standard error are presented.
In all box charts, the 25th to 75th percentiles, the median and min-max of the values are presented; *P < 0.05, **P < 0.01, ***P < 0.001. Paired t
test and/or one-way ANOVA tests
Mastelic-Gavillet et al. Journal for ImmunoTherapy of Cancer           (2019) 7:257 Page 11 of 16
ratios, however, indicates that further investigation is
needed to confirm this evidence. Notably, Ado-mediated
immunosuppression in the autologous setting was con-
comitant with a decrease in metabolic fitness (i.e. CD71
and CD98 upregulation, Fig. 4g), an increase in p-CREB
and a decrease in p-S6 activation (Fig. 4h and Additional
file 1: Figure S8e-f); these effects were also prevented by
the selective inhibition of A2AR (Fig. 4d-h). These data
suggest a predominant role of Ado in mediating the sup-
pression of human expanded TILs through A2AR signal-
ing, thus potentially jeopardizing the efficacy of adoptive
cell transfer.
Discussion
Several targets, such as CD39, CD73 and AdoRs, con-
tributing to the accumulation of Ado and its immuno-
suppressive effects in the TME are under evaluation in
preclinical and clinical studies of cancer immunother-
apy [40–43]. Ado is known to suppress tumor immun-
ity by reducing immune cell infiltration, cytotoxicity
and cytokine production [20, 43]. Moreover, CD8+ T
cell effector functions and metabolic fitness are dramat-
ically impaired in the TME [9, 10]; thus, understanding
the mechanisms of action of immunosuppressive mole-
cules is pivotal to restoring an efficient anti-tumor im-
mune response. However, mediators of Ado signaling
are not fully understood, and biomarkers of efficacy for
therapies targeting the adenosinergic pathway remain
unknown. Our study unveils new mechanisms of Ado-
mediated suppression in CD8+ T cells and highlights
potential new biomarkers to monitor during Ado-
targeted immunotherapies.
The inhibition of T cell activation in early-differentiated
cells can preclude the regeneration of the effector cells
that will die after exerting their cytotoxic/inflammatory
function. TCM cells have a longer half-life than effector
cells and an enhanced ability to divide and differentiate
into more differentiated subsets [24]. We found that hu-
man CD8+ TCM cells are the most sensitive to Ado due to
their high expression of A2AR. A high concentration of
Ado in the TME may therefore negatively affect the re-
newal of fully differentiated effector cells. Studies in both
mice and, to a lesser extent, humans support the main role
of A2AR in mediating Ado-dependent T cell immunosup-
pression and exhaustion in the TME [16, 17, 20, 21]. We
identified A2AR as the main mediator of the Ado im-
munosuppressive effect in peripheral and tumor-
infiltrating human CD8+ T cells, strengthening the
importance of this target in next-generation immuno-
therapy. As previously suggested [20, 21], we con-
firmed that the Ado/A2AR-mediated suppression in
human CD8+ T cells relies on PKA activation and in-
hibition of TCR signaling. To evaluate the expression
of the 4 AdoRs, we used RNA flow technology due to
the lack of anti-A1R and anti-A3R antibodies available
for flow cytometry. We found consistent expression
of A2A and A2B receptors measured by RNA flow
and by antibodies. However, these antibodies are not
optimal for flow cytometry since both were developed
for western blotting; anti-A2AR is against an intracel-
lular epitope, thus requiring permeabilization of the
cells and not allowing the distinction between the
surface and the intracellular compartment, while the
anti-A2BR is polyclonal, thus affecting his affinity and
specificity. Finally, these antibodies cannot be com-
bined in the same panel since A2BR staining is erased
by cell permeabilization.
Independent studies have reported the Ado inhibitory
effect on the mTORC pathway and chemotaxis in neu-
trophils [44] and the presence of a PKA-dependent man-
ner of mTORC1 inhibition in nonimmune cells that was
unrelated to the classical mTORC1 activators (i.e.,
TSC2, Rheb and Rag GTPases) [45, 46]. However, there
is no previous evidence demonstrating that Ado impairs
mTORC1 activation in an A2AR/PKA-dependent man-
ner in CD8+ T cells. Herein, we demonstrate that Ado
reduces TCR-dependent mTORC1 activation by trigger-
ing A2AR and PKA. Although mTORC1-independent
effects cannot be excluded, the importance of this com-
plex in mediating effective T cell activation [1, 4, 31, 32]
strongly suggests that, among the targets of TCR signal-
ing, impairment of mTORC1 activation is responsible
for most of the Ado/A2AR/PKA-mediated suppressive
effects in human CD8+ T cells. Notably, we show that
Ado signaling in both peripheral CD8+ T cells and TILs
exposed to autologous tumors or to polyclonal stimula-
tion not only impaired cytokine production but also
metabolic fitness. The impairment in mTORC1 activa-
tion is presumably the leading cause of the impairment
in CD8+ T cell metabolism. From a translational stand-
point, this evidence implies that Ado/A2AR-mediated
immunosuppression may be reverted as well by mole-
cules aiming at improving mTOR activation and metab-
olism selectively in T cells [47, 48]. On the other hand,
the Ado pathway may be key in leading to T cell metab-
olism uncoupling in the TME, and thus, targeting this
signaling may restore the metabolic fitness of infiltrating
T cells.
We also characterized AdoR expression in melanoma-
derived tumor cell lines and in expanded TILs. Tumor
cell lines show higher expression of A2BR than A2AR,
possibly reflecting their metastatic origin [49]. Expanded
TILs, despite a minor increase in A2BR expression, show
a prevalent and almost exclusive expression of A2AR
along with results obtained in peripheral CD8+ T cells.
In line with this evidence, we show that the sensitivity to
Ado of CD8+ TILs derived from three different tumor
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types is not different from that of peripheral CD8+ T
cells. However, TILs derived from prostate samples also
express variable amounts of A2BR, and the selective in-
hibition of this receptor prevents Ado-mediated im-
munosuppression. This effect was quantitatively
correlated with the level of A2BR expression. Although
further investigation is needed, the monitoring of A2BR
expression in TIL products may be of interest for next-
generation personalized immunotherapy in the context
of adoptive cell transfer.
Despite indications in the literature of a causal con-
nection between hypoxia and the adenosine pathway, we
did not find a correlation between the expression of
HIF-1α and A2AR. This may be explained by the lack of
a hypoxic environment in the in vitro TIL culture that is
instead present in tumor tissues.
Remarkably, Ado is able to affect both polyclonal re-
sponses of TILs derived from multiple tumors and autolo-
gous tumor-cell recognition by melanoma TILs by
reducing cytokine production and metabolic fitness. Ado
is therefore able to exert systemic immune suppression as
well as to impair antitumor activity. Along the same lines,
we show a reduction in the killing capacity of autologous
targets at some E:T ratios. This effect was barely observed
in the redirected killing assay where killing was 100%. In
vivo, however, tumor antigens are not expressed homoge-
neously throughout the tumor tissue, and their accessibil-
ity is limited to specific T cells. Thus, in this context, Ado
may exert an inhibitory effect on killing capacity. Our data
support this possibility; however, since the impairment in
the in vitro cytotoxicity observed is dependent on the E:T
ratio, further investigations are needed to explore this hy-
pothesis. The blockade of A2AR abrogated Ado-mediated
immunosuppression by preventing an increase in p-CREB
and by restoring p-S6 activity. Finally, we did not find any
effect of A2AR or A2BR inhibitors on the TIL expansion
capacity. This may be due to the absence of a significant
concentration of Ado in the culture or to the instability of
the compound used that would not allow for observing a
significant effect in long-term cultures. This should be
better investigated by using drugs currently under investi-
gation in clinical trials [50]. Nevertheless, the AdoR ex-
pression and the susceptibility of expanded TILs to Ado
immunosuppression described in our study strongly sup-
port the Ado/A2AR pathway as an important target for
cancer immunotherapy with particular relevance for com-
binatorial T cell-based strategies.
The recent remarkable clinical success of immunother-
apy brings along the need to discover predictive bio-
markers of treatment efficacy and related adverse effects.
This will help immune oncologists make decisions before
and during therapy. To date, judgements are mainly based
on the overall assessment of clinical improvement and
treatment tolerance; however, early immunomodulation
markers need to be unveiled to act faster and more specif-
ically to improve clinical success rates. In this context, we
observed that A2AR expression levels quantitatively dic-
tate CD8+ T cell sensitivity to Ado and that A2AR block-
ade rapidly affected p-CREB and p-S6 levels during
autologous tumor cell recognition. Therefore, in future
preclinical or clinical studies testing therapies targeting
the adenosinergic pathway, it will be relevant to monitor
T cell expression of A2AR to predict their sensitivity to
Ado but also of p-CREB and p-S6 to unveil their potential
as biomarkers.
Conclusions
Overall, our data support the relevance of targeting the
Ado/A2AR immunosuppressive pathway to restore both
effector function and metabolic fitness of peripheral and
tumor-derived CD8+ T cells. This could be of particular
interest in combination with adoptive cell transfer to
prevent TME immunosuppression and improve treat-
ment efficacy. Finally, we postulate that the modulation
of A2AR, p-CREB and p-S6 expression levels may be
valuable efficacy biomarkers of A2AR blockade and T
cell function recovery in the context of clinical studies.
Additional files
Additional file 1: Figure S1. Effects of Ado on CD8+ T cell cytokine
production capacity. (a) Representative example of CD8+ T cell
differentiation subsets identification by flow cytometry. (b) Representative
example of cytokine production (i.e. IFN-γ, TNF-α, IL-2 and CD107) by
CD8+ T cells stimulated overnight with anti-CD3/anti-CD28 coated beads
or PMA/Ionomycin in presence or not of Ado. (c) Cumulative data show-
ing the fold change in cytokine production (IL-2 and TNF-α) and CD107
expression by CD8+ T cells stimulated overnight with virus-specific pep-
tides (n = 11) or anti-CD3/anti-CD28 coated beads (n = 12) in uncondi-
tioned media or in presence of Ado. The 25th to 75th percentiles, the
median and min-max of the values are represented. ***P < 0.001, ****P <
0.0001, one-way ANOVA test. (d) Cumulative data showing the frequency
of cytokine production (IL-2 and TNF-α) and CD107 expression by CD8+ T
cells stimulated overnight with anti-CD3/anti-CD28 coated beads in un-
conditioned media or in presence of Ado. The 25th to 75th percentiles,
the median and min-max of the values are represented; n = 12. *P < 0.05,
**P < 0.01, Wilcoxon test. (e) Cumulative data showing the fold change in
IFN-γ production by CD8+ T cells stimulated overnight with anti-CD3/
anti-CD28 coated beads or PMA/Ionomycin in presence of Ado. The 25th
to 75th percentiles, the median and min-max of the values are repre-
sented; n = 7. ***P < 0.001, one-way ANOVA test. (f) Cumulative data of
the fold change in cytokine production (IL-2 and TNF-α) and CD107 ex-
pression after overnight stimulation with anti-CD3/anti-CD28 coated
beads in presence of Ado in distinct memory CD8+ T-cell subsets (TCM,
TEM, TEMRA). The 25th to 75th percentiles, the median and min-max of the
values are represented; n = 12. *P < 0.05, ****P < 0.0001, one-way ANOVA
test. Figure S2. Effects of Ado on CD8+ T cell functional avidity and
evaluation of AdoR expression. (a) Cumulative data of the functional sen-
sitivity (IC50 of IL-2 and TNF- α production) to Ado measured in distinct
CD8+ T cell memory subsets after overnight stimulation with anti-CD3/
CD28 beads in presence of decreasing concentrations of Ado. The 25th
to 75th percentiles, the median and min-max of the values are repre-
sented; n = 12. *P < 0.05, ****P < 0.0001, one-way ANOVA test. (b) Repre-
sentative example of AdoR expression measured by RNA flow in total
CD8 T cells. (c) Cumulative data of the AdoR expression in EBV trans-
formed B cell line, THP-1, HL-60, PC-3, LNCAP, DU145, MCF-7 measured
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by qRT-PCR. (d-e) Correlation between AdoR expression measured by
RNA flow and qRT-PCR in (d) cell lines and (e) primary human CD8 T
cells. Spearman tests. (f) Represenative example of flow cytometry stain-
ing of total CD8 T cells by anti-A2AR and anti-A2BR antibodies. (g) Correl-
ation between the expression of A2AR measured by antibody staining
and RNA staining for flow cytometry in total CD8+ T cells. Spearman test.
(h). Cumulative data of the expression of A2AR and A2BR in total CD8+ T
cells measured by antibody staining for flow cytometry. The 25th to 75th
percentiles, the median and min-max of the values are represented; n =
9. Figure S3. Functional consequences of AdoRs signaling. (a) Correlation
between A2BR expression measured by RNA flow and the Ado-mediated
fold change in IFN-γ production evaluated in total CD8+ T cells. Spear-
man test, n = 9. (b) Cumulative data showing the fold change in IFN-γ
production by distinct memory CD8+ T cell subsets (TCM, TEM, TEMRA) stim-
ulated with anti-CD3/anti-CD28 coated beads in presence of the A2AR
selective agonist CGS 21680. The 25th to 75th percentiles, the median
and min-max of the values are represented; n = 6. **P < 0.01, ***P <
0.001, one-way ANOVA test. (c) Cumulative data showing the fold change
in IFN-γ production by CD8+ T cells stimulated with anti-CD3/anti-CD28
coated beads in presence of Ado alone, or the A2AR selective antagonist
(ZM 241385) alone, or the A2BR selective antagonist (PSB 1115) alone.
The 25th to 75th percentiles, the median and min-max of the values are
represented; n = 6. ****P < 0.0001, one-way ANOVA test. Figure S4. Ado/
A2AR impact p-CREB and TCR signaling activation. (a) Representative ex-
ample of p-CREB expression detected by flow cytometry in total CD8+ T
cells after treatment with Ado or the indicated combination of A2AR
agonist (CGS 21680) and antagonist (ZM 241385) or the PKA inhibitor
(KT570). (b) Representative western blot analysis of p-CREB and CREB in
total CD8+ T whole-cell lysates after treatment with Ado or the depicted
combination of A2AR antagonist (ZM 241385) or the PKA inhibitor
(KT570). α-Tubulin was detected as a loading control. n = 3. (c) Cumula-
tive data showing the fold change in p-CREB expression by distinct mem-
ory CD8+ T cell subsets (TCM, TEM, TEMRA) in presence of Ado or the A2AR
selective agonist CGS 21680. The 25th to 75th percentiles, the median
and min-max of the values are represented; n = 7. *P < 0.05, **P < 0.01,
***P < 0.001, one-way ANOVA test. (d) Representative western blot ana-
lysis and (e) cumulative data of p-ERK and ERK in total CD8+ T whole-cell
lysates after treatment with Ado and stimulated for 3 h by anti-CD3/anti-
CD28 coated beads or the depicted combination of A2AR antagonist (ZM
241385) or the PKA inhibitor (KT570). α-Tubulin was detected as a loading
control. n = 3. Figure S5. Ado/A2AR impact p-S6 activation. The data rep-
resented in this figure were obtained analyzing CD8+ T cells stimulated
for 3h by anti-CD3/anti-CD28 coated beads under the distinct described
conditions. (a) Representative example of p-S6 expression detected by
flow cytometry after treatment with Ado or the depicted combination of
A2AR agonist (CGS 21680) and A2AR/A2BR antagonists (ZM 241385 and
PSB 1115). (b) Representative western blot analysis of p-S6 and S6 after
treatment with Ado alone or combined with the A2AR antagonist (ZM
241385) or the PKA inhibitor (KT570), Rapamycin, the AKT1/2 inhibitor
(MK2206). α-Tubulin was detected as a loading control. n = 3. (c) Repre-
sentative example of p-AktSer473 expression detected by flow cytometry
in total CD8+ T cells stimulated for 3 h by anti-CD3/anti-CD28 coated
beads in resting condition or after treatment with Ado. (d) Representative
western blot analysis of p-AktSer473 and AktSer473 after treatment with Ado
alone or combined with the A2AR antagonist (ZM 241385) or the PKA in-
hibitor (KT570), Rapamycin, the AKT1/2 inhibitor (MK2206) and stimulated
for 3 h by anti-CD3/anti-CD28 coated beads. α-Tubulin was detected as a
loading control. n = 3. (e) Cumulative data showing the fold change in p-
AktSer473 expression expression after treated with the indicated combina-
tions of Ado, A2AR agonist (CGS 21680), A2AR/A2BR antagonists (ZM
241385 and PSB 1115, respectively) or the AKT1/2 inhibitor (MK2206). The
25th to 75th percentiles, the median and min-max of the values are rep-
resented; n = 7. (f) Cumulative data showing the fold change in p-S6 ex-
pression by distinct memory CD8+ T cell subsets (TCM, TEM, TEMRA) in
presence of Ado or the A2AR selective agonist CGS 21680. The 25th to
75th percentiles, the median and min-max of the values are represented;
n = 14 and n = 12 from left to right. **P < 0.01, ***P < 0.001, ****P <
0.0001, one-way ANOVA test. Figure S6. Ado affects CD8+ T cell glyco-
lytic metabolism. (a) Representative example of CD71, CD98 expression
and 2-NBDG uptake detected by flow cytometry in total CD8+ T cells in
resting condition or after treatment with Ado and stimulated overnight
by anti-CD3/anti-CD28 coated beads. (b) Cumulative data showing the
fold change of CD71, CD98 expression and 2-NBDG uptake by distinct
memory CD8+ T cell subsets (TCM, TEM, TEMRA) stimulated overnight by
anti-CD3/anti-CD28 coated beads in resting condition or after treatment
with Ado. The 25th to 75th percentiles, the median and min-max of the
values are represented; n = 17, n = 11, n = 14 from left to right. **P <
0.01, ***P < 0.001, ****P < 0.0001, one-way ANOVA test. Figure S7. Com-
position, functionality and AdoR expression in TILs. (a) Proportion of
CD4+ and CD8+ T cells in REP expanded TILs derived from normal/in-
flamed or tumor prostate tissue and metastasis of colon cancer or of mel-
anoma. (b) Cumulative data of the frequency of cytokine-producing or
CD107+ CD8+ TILs. Each dot represents a patient, lines indicate Mean ±
SEM; n = 1. (c) Cumulative data of the fold change in IL-2, TNF-α produc-
tion and CD107 expression by TILs stimulated overnight with autologous
tumor cells in presence of Ado or ZM 241385 + Ado or PSB 1115 + Ado.
Each dot represents a patient, lines indicate Mean ± SEM; n = 14. **P <
0.01, ***P < 0.001, ****P < 0.0001, ****P < 0.0001, one-way ANOVA test. (d)
Cumulative data of the expression of AdoR in peripheral T cells from
healthy donors and in TILs derived from the depicted tissue types. The
25th to 75th percentiles, the median and min-max of the values are rep-
resented by boxes. Each dot represents a patient. The positivity threshold
is determined as 2 log higher expression than values given by water. (e)
Cumulative data of the expression of AdoR in peripheral CD8+ T cells
from healthy donors at day 0 or after 3 and 10 days stimulation with anti-
CD3/anti-CD28 coated beads. Each dot represents the mean of 8 healthy
donors analyzed. *P < 0.05, one-way ANOVA test. (f) Correlation between
the A2AR and HIF-1α expression measured by qRT-PCR in TILs. Spearman
test, n = 13. Figure S8. AdoR expression and Ado immunosuppression in
TILs/autologous tumor cells setting. (a) Cumulative data of the expression
of AdoR in peripheral melanoma-derived TILs and tumor cells. The 25th
to 75th percentiles, the median and min-max of the values are repre-
sented by boxes; n = 6. (b) Representative example of cytokine produc-
tion in melanoma-derived TILs after overnight stimulation with
autologous tumor cells in untreated culture condition, in presence of
Ado or ZM 241385 + Ado. (c) Representative example of CD71 and CD98
expression by TILs stimulated for overnight by autologous tumor cells in
resting condition, in presence of Ado or ZM 241385 + Ado. (d) Each
graph represents cytotoxicity curves for one patient quantified in resting
condition, in presence of Ado or ZM 241385 + Ado. Data are represented
as normalized to the cytotoxicity measured in absence of Ado at the
effector:target (E:T) ratio 100:1. Cytotoxicity was measured co-incubating
TILs for 4 h with P815 cell line loaded with anti-CD3 (redirected killing;
bottom graphs); n = 3, measures were performed in triplicates. (e) Repre-
sentative example of p-CREB expression by TILs in untreated culture con-
dition or in presence of Ado or ZM 241385 + Ado. (f) Representative
example of p-S6 and CD107 expression by TILs stimulated for 3 h by au-
tologous tumor cells in untreated culture condition or in presence of
Ado or ZM 241385 + Ado. (ZIP 521 kb)
Additional file 2: Table S1. Distribution of memory subsets in total and
virus-specific CD8 + T cells. Table S2: Clinical characteristics of the pa-
tients. (ZIP 61 kb)
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